Detalhe da pesquisa
1.
A randomised phase II study of osimertinib and bevacizumab versus osimertinib alone as second-line targeted treatment in advanced NSCLC with confirmed EGFR and acquired T790M mutations: the European Thoracic Oncology Platform (ETOP 10-16) BOOSTER trial.
Ann Oncol
; 33(2): 181-192, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34839016
2.
Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).
Ann Oncol
; 31(4): 495-500, 2020 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-32085891
3.
Immune checkpoint inhibitors for patients with advanced lung cancer and oncogenic driver alterations: results from the IMMUNOTARGET registry.
Ann Oncol
; 30(8): 1321-1328, 2019 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31125062
4.
[Strategies to Overcome Acquired Resistance to EGFR-TKI Therapy Based on T790M Specific Substances using Osimertinib as an Example]. / Strategien zur Überwindung der erworbenen EGFR-TKI-Resistenz durch T790M spezifische Substanzen am Beispiel von Osimertinib.
Pneumologie
; 72(11): 774-781, 2018 Nov.
Artigo
em Alemão
| MEDLINE | ID: mdl-30408830
5.
Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non-small cell lung cancer in Switzerland: A comprehensive evaluation of real world practices.
Eur J Cancer Care (Engl)
; 26(6)2017 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-28557060
6.
Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort.
Ann Oncol
; 27(2): 281-6, 2016 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-26598547
7.
Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upâ.
Ann Oncol
; 32(7): 839-853, 2021 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-33864941
8.
EGFR mutation subtype impacts efficacy of immune checkpoint inhibitors in non-small-cell lung cancer.
Ann Oncol
; 30(8): 1190-1192, 2019 08 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31198952
9.
Patterns of progression on first line osimertinib in patients with EGFR mutation-positive advanced non-small cell lung cancer (NSCLC): A Swiss cohort study.
Lung Cancer
; 187: 107427, 2024 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-38043395
10.
Management of elderly patients with advanced non-small cell lung cancer: a single-center experience.
Chemotherapy
; 59(1): 42-50, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23838903
11.
Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14.
ESMO Open
; 8(4): 101595, 2023 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-37441877
12.
Long-term benefit of lurbinectedin as palliative chemotherapy in progressive malignant pleural mesothelioma (MPM): final efficacy and translational data of the SAKK 17/16 study.
ESMO Open
; 7(3): 100446, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35427834
13.
Impact of smoking status on the relative efficacy of the EGFR TKI/angiogenesis inhibitor combination therapy in advanced NSCLC-a systematic review and meta-analysis.
ESMO Open
; 7(3): 100507, 2022 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-35696746
14.
Long-term outcomes of operable stage III NSCLC in the pre-immunotherapy era: results from a pooled analysis of the SAKK 16/96, SAKK 16/00, SAKK 16/01, and SAKK 16/08 trials.
ESMO Open
; 7(2): 100455, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35398718
15.
Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis.
Ann Oncol
; 22(3): 567-574, 2011 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-20843984
16.
Preoperative chemoradiotherapy with cisplatin and docetaxel for stage IIIB non-small-cell lung cancer: 10-year follow-up of the SAKK 16/01 trial.
Ann Oncol
; 27(10): 1971-3, 2016 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-27358380
17.
1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer.
Ann Oncol
; 22(9): 1973-1980, 2011 Sep.
Artigo
em Inglês
| MEDLINE | ID: mdl-21727198
18.
Choice of second-line systemic therapy in stage IV small cell lung cancer (SCLC) - A decision-making analysis amongst European lung cancer experts.
Lung Cancer
; 146: 6-11, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32485661
19.
Treatment of brain metastases in small cell lung cancer: Decision-making amongst a multidisciplinary panel of European experts.
Radiother Oncol
; 149: 84-88, 2020 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-32445987
20.
Patterns of progression on osimertinib in EGFR T790M positive NSCLC: A Swiss cohort study.
Lung Cancer
; 130: 149-155, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30885336